PerkinElmer Offers First Commercially Available Newborn Screen for Severe
Combined Immunodeficiency (SCID) in Europe & the Middle East
SCID screening improves medical outcomes with early detection, intervention
WALTHAM, Mass. -- August 29, 2013
PerkinElmer, Inc., a global leader in improving the health and safety of
people and the environment, today introduced the first commercially available
screening test for Severe Combined Immunodeficiency (SCID). The EnLite™
Neonatal TREC System expands the newborn screening portfolio of commercially
available tests and will be introduced under CE marking, for sale in select
countries in Europe and the Middle East.
SCID impacts an estimated 1 in 50,000 to 1 in 100,000 newborns globally every
year. The disease is a genetic disorder that can reduce lifespan but it can be
treated when detected early in newborns. Treatments include bone marrow or
cord blood transplant (BMT/CBT) from a family member or donor. PerkinElmer’s
new SCID screening test provides a benefit over current laboratory tests by
reducing steps in the workflow, thus increasing screening efficiency.
Implementing screening for early detection of SCID as part of a newborn
screening program provides a cost benefit compared to the greater costs of
managing the disease when detected later. This is due to fewer complications
that require prolonged and intensive care as a result of the earlier detection
and diagnosis of SCID.
“PerkinElmer has been a global leader in newborn screening for more than 25
years. Our new SCID screening test is the direct result of our extensive
expertise, knowledge and commitment to ensuring that newborn screening
laboratories have access to the most advanced testing products for improving
the health of babies,” said Jim Corbett, president, Diagnostics and Life
Sciences and Technology, PerkinElmer. “We are pleased to offer this new
screening test to many countries in Europe and the Middle East so that they
can incorporate it as part of their pre-existing newborn screening programs
for early detection of this genetic disorder and timely clinical intervention
for improved medical outcomes.”
“We have seen that early clinical intervention is key to allowing effective
management for patients with Severe Combined Immunodeficiency,” said Bobby
Gaspar, M.D, Ph.D., Professor of Pediatrics and Immunology at London’s Great
Ormond Street Hospital for Children and the UCL Institute of Child Health.
“With the availability of PerkinElmer’s new test for screening SCID,
clinicians will be able to diagnose patients more quickly and precisely,
improving quality of life and transplant outcome for newborns affected by this
highly debilitating and potentially fatal condition.”
Screening through the EnLite™ Neonatal TREC System is intended to provide
accurate results and minimize the number of steps taken towards a SCID
diagnosis. The simplified procedure is designed to be cost effective and fit
within the existing newborn screening processes that are utilized by
laboratories. The test has been designed to minimize manual work and the risk
of contamination by reducing the number of transfer steps. The test includes
software-aided traceability for the workflow that is intended to improve
safety and efficacy in the screening use.
To learn more about PerkinElmer’s newborn screening platforms, visit:
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com. Join the conversation and follow us on twitter at
About Great Ormond Street Hospital for Children NHS Foundation Trust
The UCL Institute of Child Health, in partnership with Great Ormond Street
Hospital (GOSH), is the largest centre in Europe devoted to clinical and basic
research and postgraduate teaching in children’s health. Academics at the UCL
Institute of Child Health work together with clinicians at GOSH to form an
integrated and multi-disciplinary approach to the understanding, diagnosis,
treatment and prevention of childhood disease. Many individuals hold joint
appointments at both institutions. This allows the hospital and the institute
to work together to translate research undertaken in laboratories into
clinical trials and treatments in the hospital, bringing real benefits to the
children at GOSH and to the wider paediatric community. See
www.ucl.ac.uk/ich/homepage for more information.
Edelman (On behalf of PerkinElmer, Inc.)
Jen Reid, 404-460-8587
Press spacebar to pause and continue. Press esc to stop.